Search Results - "Lee, J. L."

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma by Rosenberg, J.E., Powles, T., Sonpavde, G.P., Loriot, Y., Duran, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Mamtani, R., Wu, C., Matsangou, M., Campbell, M., Petrylak, D.P.

“…This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of ∼2 years from EV-301…”
Get full text

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma by Bellmunt, Joaquim, de Wit, Ronald, Vaughn, David J, Fradet, Yves, Lee, Jae-Lyun, Fong, Lawrence, Vogelzang, Nicholas J, Climent, Miguel A, Petrylak, Daniel P, Choueiri, Toni K, Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I, Culine, Stéphane, Sternberg, Cora N, Mai, Yabing, Poehlein, Christian H, Perini, Rodolfo F, Bajorin, Dean F

“…In a randomized trial involving 542 patients with relapsed urothelial cancer, treatment with pembrolizumab resulted in overall survival of more than 10 months,…”
Get full text

Analysis of Improved Nutritional Composition of Potential Functional Food (Okara) after Probiotic Solid-State Fermentation by Gupta, Sulagna, Lee, Jaslyn J. L, Chen, Wei Ning

“…Okara is a major agro-waste, generated as a byproduct from the soymilk and tofu industry. Since okara has a high nutritive value, reusing it as a substrate for…”
Get full text

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up by Balar, A.V., Castellano, D.E., Grivas, P., Vaughn, D.J., Powles, T., Vuky, J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Necchi, A., Petrylak, D.P., Plimack, E.R., Xu, J.Z., Imai, K., Moreno, B.H., Bellmunt, J., de Wit, R., O’Donnell, P.H.

“…Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response…”
Get full text

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma by Koh, Y., Lim, H.Y., Ahn, J.H., Lee, J.-L., Rha, S.Y., Kim, Y.J., Kim, T.M., Lee, S.-H.

“…We investigated the efficacy of everolimus against nonclear-cell renal cell carcinoma (nccRCC). Patients with nccRCC received 10-mg everolimus once daily until…”
Get full text

Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma by Lee, J.-L., Ahn, J.-H., Lim, H.Y., Park, S.H., Lee, S.H., Kim, T.M., Lee, D.-H., Cho, Y.M., Song, C., Hong, J.H., Kim, C.-S., Ahn, H.

“…Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC). Eligibility…”
Get full text

Thalamic adenylyl cyclase 1 is required for barrel formation in the somatosensory cortex by Suzuki, A, Lee, L.-J, Hayashi, Y, Muglia, L, Itohara, S, Erzurumlu, R.S, Iwasato, T

“…Highlights • Mice devoid of thalamic adenylyl cyclase 1 (AC1) are generated. • Thalamic AC1 is required for cortical barrel formation. • Thalamic AC1 is…”
Get full text

Organic Depth Profiling of a Nanostructured Delta Layer Reference Material Using Large Argon Cluster Ions by Lee, J. L. S, Ninomiya, S, Matsuo, J, Gilmore, I. S, Seah, M. P, Shard, A. G

“…Cluster ion beams have revolutionized the analysis of organic surfaces in time-of-flight secondary ion mass spectrometry and opened up new capabilities for…”
Get full text

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib by Lee, W.J., Lee, J.L., Chang, S.E., Lee, M.W., Kang, Y.K., Choi, J.H., Moon, K.C., Koh, J.K.

“…Summary Background  The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and…”
Get full text

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC by Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C

“…Background: Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of therapy. Benchmarks for survival…”
Get full text

Challenges to optimal rheumatology care: a patient-centered focus group study by Dollinger, J., Neville, C., Pineau, C. A., Vinet, E., Hazel, E., Lee, J. L. F., Bernatsky, S.

“…Objective To assess challenges to optimal rheumatology care from the perspective of patients served by our institution’s rheumatology division. Design setting…”
Get full text

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer by Yoo, C, Hwang, J Y, Kim, J-E, Kim, T W, Lee, J S, Park, D H, Lee, S S, Seo, D W, Lee, S K, Kim, M-H, Han, D J, Kim, S C, Lee, J-L

“…Background: Only a few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based…”
Get full text

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma by Lee, J.-L., Park, S. I., Kim, S.-B., Jung, H.-Y., Lee, G. H., Kim, J.-H., Song, H.-Y., Cho, K.-J., Kim, W.-K., Lee, J.-S., Kim, S.-H., Min, Y.-I.

“…Background: We conducted a prospective randomized controlled trial comparing surgery alone (S) with concurrent chemoradiotherapy followed by surgery (CRT-S)…”
Get full text

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum by Yoon, D H, Ryu, M-H, Park, Y S, Lee, H J, Lee, C, Ryoo, B-Y, Lee, J-L, Chang, H-M, Kim, T W, Kang, Y-K

“…Background: To evaluate the activity and safety of everolimus and identify potential biomarkers for efficacy of everolimus in patients with advanced gastric…”
Get full text

Evaluation of brewers’ spent grain as a novel media for yeast growth by Cooray, Sachindra T., Lee, Jaslyn J. L., Chen, Wei Ning

“…Brewers’ spent grain (BSG) is a by-product generated from the beer manufacturing industry, which is extremely rich in protein and fiber. Here we use low cost…”
Get full text

Analysis of water-level response to rainfall and implications for recharge pathways in the Chalk aquifer, SE England by Lee, L.J.E., Lawrence, D.S.L., Price, M.

“…Water table response to rainfall was investigated at six sites in the Upper, Middle and Lower Chalk of southern England. Daily time series of rainfall and…”
Get full text

Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure by Manakkat Vijay, Godhev K, Ryan, Jennifer M, Abeles, Robin D, Ramage, Stephen, Patel, Vishal, Bernsmeier, Christine, Riva, Antonio, McPhail, Mark J W, Tranah, Thomas H, Markwick, Lee J L, Taylor, Nicholas J, Bernal, William, Auzinger, Georg, Willars, Chris, Chokshi, Shilpa, Wendon, Julia A, Ma, Yun, Shawcross, Debbie L

“…OBJECTIVES:There is a marked propensity for patients with acetaminophen-induced acute liver failure to develop sepsis, which may culminate in multiple organ…”
Get full text

Development of a two-step, non-probed multiplex real-time PCR for surveilling Vibrio anguillarum in seawater by Hickey, M E, Richards, G P, Lee, J-L

“…Vibrio anguillarum is an aggressive and halophilic bacterial pathogen most commonly originating from seawater. Vibrio anguillarum presence in fisheries and…”
Get full text

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients by Wang, Y, Choueiri, T K, Lee, J-L, Tan, M-H, Rha, S Y, North, S A, Kollmannsberger, C K, McDermott, D F, Heng, D Y C

“…Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic…”
Get full text

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group by Kim, T.M., Lee, S.-Y., Jeon, Y.K., Ryoo, B.-Y., Cho, G.J., Hong, Y.S., Kim, H.J., Kim, S.-Y., Kim, C.S., Kim, S., Kim, J.S., Sohn, S.K., Song, H.H., Lee, J.L., Kang, Y.K., Yim, C.Y., Lee, W.S., Yuh, Y.J., Kim, C.W., Heo, D.S.

“…This national survey was undertaken to propose the classification of extranodal natural killer (NK)/T-cell lymphoma (NTCL) subtypes and to clarify a clinical…”
Get full text